CF case study: How patients can get costly orphans reimbursed
This article was originally published in Scrip
Executive Summary
Companies that want to secure reimbursement for their expensive orphans could learn much from what happened in Ireland with Vertex' cystic fibrosis drug Kalydeco (ivacaftor). When the local health technology assessment recoiled at its €234,000 price tag, patients stepped in to show the National Centre for Pharmacoeconomics the drug's true value.
You may also be interested in...
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.
Germany Courts Clinical Trials With Regulator Reshuffle & New Federal Ethics Committee
Plans to rejig two regulators’ roles and streamline the ethics committee system have drawn some criticism.